Bill Roth

Manufacturers must forecast and commercialize products across commercial, government and cash economies to maximize lifetime enterprise value.

Cash pay is re-emerging as biopharma brands rethink insurance barriers, patient access, and affordability in a fragmented payer market.

The commercial PBM model is confronting structural strain as market forces—not regulation—begin to expose the fragility of high-rebate pricing economics.

Bill Roth, general manager and managing partner of IntegriChain’s consulting business, previews his new six-part series by outlining how rising payer fragmentation, divergent cash and insurance models, and supply-chain constraints are reshaping brand strategy.

In a wide-ranging keynote on disruption across pharmaceutical channels, Bill Roth, general manager and managing partner of IntegriChain’s consulting business, outlines why 2025 marks the beginning of a profound regulatory and commercial transformation—from sweeping policy shifts and accelerating WAC reductions to new debates on direct-to-patient strategies and looming instability in medical benefit reimbursement.

The fracturing of the US drug market’s traditional model is forcing a demand for a strategic bifurcation to maintain profitability, compliance, and patient access in the decade ahead.

From patent cliffs and government price controls, to self-pay models and staff-model HMOs, a look at the forces that could deflate the bubble—and those factors likely to keep it afloat a while longer.

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.

A look at the actionable steps needed to elicit change.

A crash course on the bubble itself, including therapeutic areas most affected.

Why this trend is occurring and ways that drugmakers are pivoting in order to remedy the situation.

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.

A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

The trend is continuing for brands and even for some specialty products.

How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.